Global Leukemia Academy
Emerging and Practical Concepts and Controversies in Leukemias
Overview
In recent years progress in the molecular understanding of acute leukemias has led to greatly improved comprehension of these diseases, and novel approved therapies are changing treatment paradigms. Aptitude Health has developed the Global Leukemia Academy and is organizing a series of meetings in 2020 to help physicians better understand how the emerging therapies and concepts are being adapted globally, and to address barriers between innovation and implementation for patient care.
Date and Location
8–9 July 2020
Virtual Meeting
Meeting Content
View the slides and watch the video of the Day 1
ALL Plenary Session
Faculty
Patrick A. Brown, MD
Johns Hopkins University
School of Medicine, USA
Fatih Demirkan, MD
Dokuz Eylul University, Turkey
Elias Jabbour, MD
The University of Texas MD Anderson Cancer Center, USA
Hale Ӧren, MD
Dokuz Eylul University, Turkey
Rob Pieters, MD, PhD
Princess Máxima Center for Pediatric Oncology,
University of Utrecht, The Netherlands
José Maria Ribera, MD
Catalan Institute of Oncology, University Hospital Germans Trias i Pujol, Spain
Andre Schuh, MD
Princess Margaret Cancer Centre, Canada
|
Agenda |
The virtual program ran over 2 days. Day 1: Plenary Session ALL Day 2: Parallel breakout sessions, Pediatric and Adult ALL |
| DAY 1: Virtual Plenary sessions |
Time UTC+3 | Title | Speaker |
| Wednesday, 8 July 2020 from 15.00 – 19.00 (UTC+3) | 15.00 – 15.10 | Welcome and meeting overview Introduction to the voting system |
Elias Jabbour Fatih Demirkan |
| 15.10 – 15.25 | Review of prognostic value of MRD in ALL | Elias Jabbour | |
| 15.25 – 15.40 | How and when to check for MRD in ALL | José Maria Ribera | |
| 15.40 – 15.55 | CR1 vs CR2 – where is MRD control more useful and how to achieve it? | Elias Jabbour | |
| 15.55 – 16.10 | AYA ALL patients – what is the current treatment approach for this diverse patient population? | Rob Pieters | |
| 16.10 – 16.25 | Bispecific T-cell engagers as post-reinduction therapy improves survival in pediatric and AYA B-ALL | Patrick Brown | |
| 16.25 – 16.45 | Coffee break | ||
| 16.45 – 17.00 | Genetic variants in ALL – Ph+ and Ph-like | Andre Schuh | |
| 17.00 – 17.45 | Panel discussion on the role of HSCT • Experience of HSCT in the region • Pros and cons of HSCT • How does COVID-19 influence your approach? • Discussion and voting |
Fatih Demirkan Fatih Demirkan, Andre Schuh All faculty All faculty |
|
| 17.45 – 18.25 | Debate on CD19-targeted approaches • CAR T • Monoclonal antibodies and bispecifics • Discussion and voting |
José Maria Ribera Elias Jabbour All faculty |
|
| 18.25 – 18.55 | Emerging data and the management of ALL patients during COVID-19 • Presentation • Panel discussion |
Fatih Demirkan Elias Jabbour All faculty |
|
| 18.55 – 19.00 | Session close | Elias Jabbour Fatih Demirkan |
| DAY 2: Virtual Breakout 1: Pediatric ALL patients |
Time UTC+3 | Title | Speaker |
| Thursday, 9 July 2020 from 15.00 – 17.10 (UTC+3) | 15.00 – 15.15 | Session opening • Educational ARS questions for the audience |
Rob Pieters |
| 15.15 – 15.35 | First-line treatment of pediatric ALL • Presentation • Q&A |
Rob Pieters | |
| 15.35 – 15.55 | Current treatment options for relapsed ALL in children, including HSCT considerations • Presentation • Q&A |
Hale Ören | |
| 15.55 – 16.15 | Bispecific T-cell engagers for pediatric ALL • Presentation • Q&A |
Patrick Brown | |
| 16.15 – 16.55 | Case-based panel discussion Management of long- and short-term toxicities • Overview of long-term toxicities • Patient case presentation Panelists: Rob Pieters, Hale Ören, Patrick Brown, Akif Yesilipek, Sema Anak |
Rob Pieters, Hale Ӧren All panelists |
|
| 16.55 – 17.10 | Session close • Educational ARS questions for the audience |
Rob Pieters |
| DAY 2: Virtual Breakout 2: Adult ALL patients |
Time UTC+3 | Title | Speaker |
| Thursday, 9 July 2020 from 15.00 – 17.00 (UTC+3) | 15.00 – 15.15 | Session opening • Educational ARS questions for the audience |
Elias Jabbour |
| 15.15 – 15.35 | Optimizing first-line therapy in adult and older ALL – integration of immunotherapy into frontline regimens • Presentation • Q&A |
Elias Jabbour | |
| 15.35 – 15.55 | Current treatment options for relapsed ALL in adult and elderly patients • Presentation • Q&A |
Fatih Demirkan | |
| 15.55 – 16.45 | Case-based panel discussion Management of long- and short-term toxicities and treatment selection in adult and elderly patients Panelists: Elias Jabbour, Fatih Demirkan, Andre Schuh, José Maria Ribera |
Fatih Demirkan, Andre Schuh All panelists |
|
| 16.45 – 17.00 | Session close • Educational ARS questions for the audience |
Elias Jabbour |
